Video

Data

Text duration start ents sentiment
well looking at the fourth quarter it 3.2 Jump to 0.08
    DATE the fourth quarter
at a dollar eighty per share versus a 4.0 Jump to 4.88
    CARDINAL eighty
dollar fifty three analysts were looking 4.639 Jump to 7.12
    CARDINAL fifty three
for revenue uh was 13.52 billion ahead 5.12 Jump to 8.88
    MONEY 13.52 billion
of the 13.16 billion that analysts were 4.881 Jump to 11.759
    MONEY the 13.16 billion
looking for for 2022 the sales outlook 4.08 Jump to 14.0
    DATE 2022
expectations 56.1 billion to 57.6 5.76 Jump to 18.08
    CARDINAL 56.1 billion
    CARDINAL 57.6
billion however adjusted eps giving a 5.28 Jump to 21.68
range of 712 to 727 a share looks two 4.8 Jump to 23.84
    CARDINAL 712
    CARDINAL 727
    CARDINAL two
for at 7 4.079 Jump to 28.64
29. the company also slightly reducing 4.559 Jump to 29.84
    CARDINAL 29
piravir it's covered 19 drug now looking 4.241 Jump to 34.399
    CARDINAL 19
at five to six billion dollars in sales 3.921 Jump to 36.399
    MONEY five to six billion dollars
in 2022 for that drug they had 3.84 Jump to 38.64
    DATE 2022
previously forecast up to 7 billion 4.239 Jump to 40.32
    MONEY 7 billion
challenging year in 2021 for all of us 4.479 Jump to 60.64
    DATE 2021
growth as you pointed out 24 percent 4.56 Jump to 69.52
    PERCENT 24 percent
growth in the quarter 17 percent growth 5.441 Jump to 71.439
    DATE the quarter
    PERCENT 17 percent
out of 2021 with great momentum as we go 5.441 Jump to 112.079
    DATE 2021
into 2022. 4.559 Jump to 114.56
    DATE 2022
expectations coming in about a hundred 3.52 Jump to 131.12
    CARDINAL about a hundred
million dollars ahead of what they might 3.28 Jump to 132.48
grew very strongly it grew 18 6.159 Jump to 144.08
    CARDINAL 18
as we look at it for the full year 16 in 4.4 Jump to 147.76
    DATE the full year 16
into the third quarter 4.239 Jump to 167.28
    DATE the third quarter
now the number one drug in that market 5.68 Jump to 201.44